Global Wegener’s Granulomatosis Treatment Market Report and Forecast 2024-2032

Global Wegener’s Granulomatosis Treatment Market Outlook

The Wegener’s granulomatosis treatment market is estimated grow at a CAGR of 5.90% in the forecast period of 2024-2032. The market is expected to grow owing to the increasing prevalence of Wegener’s granulomatosis and improved governmental and private actions to increase understanding about the right diagnosis and treatment of such a rare ailment.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Wegener’s Granulomatosis Insights

GPA, or granulomatosis with polyangiitis (Wegener's), is a rare blood vessel disease. It is a potentially fatal autoimmune illness with an unclear cause. Since the inflammation in the blood vessel prevents optimal blood flow, the cells do not receive the oxygen they require. This results in tissue damage known as granulomatous inflammation. A granuloma is a form of cellular inflammation that is typically seen in biopsies of damaged organs.  The traditional clinical triad includes necrotizing granulomatous inflammation of the upper and/or lower respiratory tract, necrotizing glomerulonephritis, and an autoimmune necrotizing systemic vasculitis that primarily affects tiny arteries.

This rare condition is believed to impact 3 people out of every 100,000. It has an equal impact on males and women. GPA can happen at any age, although it is most common between the ages of 40 and 65. It is uncommon in children.

There is no single exam for determining GPA. Many factors contribute to GPA diagnosis, including symptoms, physical examination, blood testing, and imaging procedures like X-rays, CT scans, or MRI.

Active GPA produces inflammation in the blood vessels and organs. Chronic inflammation in blood arteries or organs can lead to organ failure. Without therapy, GPA can rapidly develop, potentially leading to life-threatening kidney or lung failure. 

Those with active severe disease are frequently given a glucocorticoid (steroid) medicine, such as Prednisone in combination with Cyclophosphamide (Cytoxan), a chemotherapy treatment. Prednisone is given at a high dose and progressively tapered off over a period of weeks to months. Cyclophosphamide is administered orally or by injection for three to six months. Those who improve are subsequently shifted to another medicine for 2 or more years, such as Methotrexate (Rheumatrex, Trexall) or Azathioprine (Imuran, Azasan). Prednisone and Methotrexate may be used to treat those with less active illness.

According to the Wegener’s granulomatosis treatment market research report, the market can be categorised into the following segments: 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Diagnosis

• Lab Test
  • Blood Test
  • Urine Test
• Imaging Tests
  • Chest X-rays
  • CT Scan
  • MRI
• Biopsy

Market Breakup by Drug

• Medication
  • Steroids
  • Immunosuppressant
  • Others
• Plasma Exchange

Wegener’s Granulomatosis Treatment Market Breakup by Route of Administration

• Oral

• Intravenous

• Others

Market Breakup by Therapeutic Channel

• Public

• Private

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Wegener’s Granulomatosis Epidemiology

The global prevalence is predicted to be between 1/6,400 and 42,000, with an annual incidence of 1/84,000 to 475,000. There is geographic and/or ethnic variation, with colder places and Caucasians having a higher occurrence. Childhood-onset disease has a female predominance, whereas adult-onset disease has a little male predominance.

Wegener’s Granulomatosis Treatment Market Drivers

The North American region is likely to lead the market throughout the projection period due to the higher incidence rate of Wegener’s granulomatosis. 3 per 100,000 people are affected by Wegener’s granulomatosis.    

Due to high prevalence rates, improved healthcare infrastructure and amenities, increased government activities, rising disposable income in this region, expansion of the healthcare system, and increasing approval rates for additional novel medications, the Asia Pacific region is expected to grow at the fastest rate. The market expansion is being driven by the region’s rapidly expanding healthcare infrastructure, particularly in China and India, and the region’s increased awareness of rare disease treatment.

Clinical studies and increased R&D spending have allowed for the introduction of novel medicine molecules to the market. The companies are developing potential drug options to improve the treatment of GPA. 

Additionally, enhanced governmental and private actions to increase information regarding correct diagnosis and treatment of such a rare ailment, technology improvements, increased public health awareness, and favourable reimbursement rules will boost the market expansion.

Therapeutic Trends and Innovation

The increased use of monoclonal antibodies and recent advances in systemic treatment of Wegener's granulomatosis, including the introduction of investigational immunosuppressive drugs, such as Etanercept, Leflunomide, and Deoxyspergualin, are expected to shift the conventional treatment paradigm.

ChemoCentryx, Inc. gained USFDA approval for TAVNEOS (avacopan) in October 2021. It is used to treat adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA vasculitis), specifical Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). It is an orally administered selective complement 5a receptor inhibitor used in conjunction with conventional therapy.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the Wegener’s granulomatosis treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

• Sonoma Pharmaceuticals, Inc.

• GSK plc

• Halozyme Therapeutics, Inc

• Sun Pharmaceutical Industries

• Teva Pharmaceutical Industries

• Aprogen, Inc.

• Amgen, Inc.

• Epirus Biopharmaceuticals, Inc.

• Pfizer Inc.

• Novartis AG

Key Highlights of the Report

Wegener’s Granulomatosis Treatment Market Report Snapshots

Wegener’s Granulomatosis Treatment Market Size

Wegener’s Granulomatosis Treatment Companies